Prostate Cancer | Specialty

Role of Corticosteroids Unclear for Men With mCRPC

January 31st 2014

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.

Three Studies Provide Insights About Combining/Sequencing Abiraterone

January 31st 2014

Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate

Follow-up Confirms Safety of Radium-223 in mCRPC

January 31st 2014

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.

Dr. Gomella Discusses New Data on Sipuleucel-T

January 31st 2014

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

Dr. Neal Shore Discusses ODM-201 in CRPC

January 30th 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.

Dr. Tagawa on Abiraterone Plus Docetaxel in mCRPC

January 30th 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.

Long-Term Data Show Continued Improved Outcomes for Radiotherapy/Antiandrogen Combination in Locally Advanced Prostate Cancer

January 29th 2014

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

Pre-Chemo Enzalutamide OS Benefit in mCRPC Reaches Nearly 30%

January 28th 2014

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

Dr. Shore on Genomic Assays in Prostate Cancer

January 27th 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses genomic assays in prostate cancer.

Sequencing Puzzles in CRPC Therapies Remain Unsolved

January 23rd 2014

So many new agents for the treatment of men with castration-resistant prostate cancer (CRPC) have been introduced in the past several years that optimal sequencing of therapies remains an unsettled question.

Overuse of Bone Scans Demonstrated in Low- and Intermediate-Risk Patients with Prostate Cancer

January 17th 2014

Researchers in the Department of Radiation Oncology at the University of North Carolina Hospitals found that almost one-third of low-risk and almost one-half of intermediate-risk prostate cancer patients received a staging bone scan.

Dr. Mehlhaff on Prostate Cancer Screening Guidelines

January 16th 2014

Bryan A. Mehlhaff, MD, from the Oregon Urology Institute, discusses prostate cancer screening guidelines.

Study: Degarelix Before Leuprolide Can Eliminate Testosterone Surge

December 31st 2013

Patients who undergo androgen deprivation therapy (ADT) to manage advanced prostate cancer will often face the prospect of a potentially dangerous testosterone surge before the downregulation of leuteinizing hormone (LH) secretion occurs and, within about 3 weeks, testosterone drops to castration-like levels.

Hot Flash Treatments That Help Women Fail to Benefit Androgen-Deprived Men

December 20th 2013

Men who experience hot flashes because they are undergoing androgen-deprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate that symptom in menopausal women, the results of a study show.

Managing Bone Health in Advanced Lung Cancer

December 19th 2013

Managing Bone Health in Breast Cancer

December 19th 2013

Managing Bone Health in Prostate Cancer

December 19th 2013

AR-Targeted Therapies in Advanced Prostate Cancer

December 18th 2013

Multidisciplinary Prostate Cancer Care

December 18th 2013

Radium-223 in CRPC With Bone Metastases

December 18th 2013